

# (12) International Application Status Report

**Received at International Bureau:** 30 March 2017 (30.03.2017)

**Information valid as of:** 07 September 2018 (07.09.2018)

**Report generated on:** 07 April 2019 (07.04.2019)

**(10) Publication number:**

WO2017/161370

**(43) Publication date:**

21 September 2017 (21.09.2017)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/US2017/023206

**(22) Filing Date:**

20 March 2017 (20.03.2017)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

62/310,409 (US)

**(31) Priority date(s):**

18 March 2016 (18.03.2016)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

*A61K 31/5517* (2006.01); *A61P 25/18* (2006.01)

**(71) Applicant(s):**

UWM RESEARCH FOUNDATION, INC. [US/US]; 1440 East North Avenue Milwaukee, WI 53202 (US) *(for all designated states)*

CENTRE FOR ADDICTION AND MENTAL HEALTH [CA/CA]; 1001 Queen Street West Toronto, ON M6J 1H4 (CA) *(for all designated states)*

UNIVERSITY OF BELGRADE - FACULTY OF PHARMACY [RS/RS]; Vojvode Stepe 450 Belgrade, 11221 (RS) *(for all designated states)*

**(72) Inventor(s):**

COOK, James M.; 6139 N. Lake Drive Milwaukee, WI 53217 (US)

LI, Guangan; 2020 E. Park Place, Apartment 104 Milwaukee, WI 53211 (US)

POE, Michael, Ming-Jin; 1100 Hartford Turnpike, Apt. 54 Vernon, CT 06066 (US)

SAVIC, Miroslav M.; Paunova 41 Belgrade, 11000 (RS)

SIBILLE, Etienne; 11 St-Joseph Street, #1008 Toronto, ON M4Y 3G4 (CA)

**(74) Agent(s):**

YAGER, Charlene L.; Michael Best & Friedrich LLP 100 East Wisconsin Avenue, Suite 3300 Milwaukee, WI 53202-4108 (US)

**(54) Title (EN):** TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABA<sub>A</sub> RECEPTOR AGONISTS

**(54) Title (FR):** TRAITEMENT DES SYMPTÔMES COGNITIFS ET DES TROUBLES DE L'HUMEUR DANS DES TROUBLES NEURODÉGÉNÉRATIFS ET NEUROPSYCHIATRIQUES AVEC DES AGONISTES DU RÉCEPTEUR GABA<sub>A</sub> CONTENANT ALPHA5

**(57) Abstract:**

**(EN):** Provided herein are alpha5-containing GABA<sub>A</sub> receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

**(FR):** L'invention concerne des agonistes du récepteur GABA<sub>A</sub> contenant alpha5, des compositions pharmaceutiques utilisant ces agonistes, et des procédés de traitement des symptômes cognitifs et des troubles de l'humeur dans des troubles neurodégénératifs et neuropsychiatriques au moyen de ces agonistes.

**International search report:**

Received at International Bureau: 01 July 2017 (01.07.2017) [US]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

**(81) Designated States:**

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM